Avanir ends R&D agreements with Novartis, AstraZeneca

Share this article:
Avanir Pharmaceuticals announced that it has ended two drug development collaboration deals -- one with AstraZeneca and one with Novartis -- and is exploring the sale of certain assets. Novartis, which was developing inflammatory disease treatment AVP-28225 with Avanir, will further develop the compound on its own. Avanir will receive a milestone payment if the compound reaches the next stage of development. Avanir also said it would return to AstraZeneca the drug the companies were co-developing for cardiovascular diseases. Avanir would also return all related rights to AstraZeneca, Avanir said in a statement. Additionally, Avanir said it plans to exit its San Diego research facility later this year and move clinical development and support resources to its Orange County, CA headquarters. Avanir is also evaluating options including sale of several investigational compounds and its schizophrenia drug FazaClo, which contributed $6.3 million to Avanir’s sales in the first quarter.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.